ZA201907687B - Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same - Google Patents

Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Info

Publication number
ZA201907687B
ZA201907687B ZA2019/07687A ZA201907687A ZA201907687B ZA 201907687 B ZA201907687 B ZA 201907687B ZA 2019/07687 A ZA2019/07687 A ZA 2019/07687A ZA 201907687 A ZA201907687 A ZA 201907687A ZA 201907687 B ZA201907687 B ZA 201907687B
Authority
ZA
South Africa
Prior art keywords
salt
preparing
same
crystalline form
derivative compound
Prior art date
Application number
ZA2019/07687A
Other languages
English (en)
Inventor
Sang Ho Oh
Jong Gyun Kim
Se-Woong Oh
Tae Dong Han
Soo Yong Chung
Seong Ran Lee
Kyeong Bae Kim
Young Sung Lee
Woo Seob Shin
Hyun Ju
Jeong Ki Kang
Su Min Park
Dong Kyun Kim
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201907687(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of ZA201907687B publication Critical patent/ZA201907687B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2019/07687A 2017-04-21 2019-11-20 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same ZA201907687B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Publications (1)

Publication Number Publication Date
ZA201907687B true ZA201907687B (en) 2023-04-26

Family

ID=63857137

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07687A ZA201907687B (en) 2017-04-21 2019-11-20 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Country Status (23)

Country Link
US (3) US11453656B2 (zh)
EP (1) EP3612529A4 (zh)
JP (2) JP7126514B2 (zh)
KR (2) KR102629654B1 (zh)
CN (1) CN110869367B (zh)
AR (1) AR111469A1 (zh)
AU (2) AU2018256227B2 (zh)
BR (1) BR112019021868A2 (zh)
CA (1) CA3059543A1 (zh)
CO (1) CO2019011578A2 (zh)
EA (1) EA201992501A1 (zh)
IL (2) IL294666B2 (zh)
MA (1) MA49696A (zh)
MX (1) MX2022006357A (zh)
MY (1) MY201919A (zh)
NZ (1) NZ758443A (zh)
PH (1) PH12019502370A1 (zh)
SA (1) SA519410342B1 (zh)
SG (1) SG11201909615YA (zh)
TW (1) TWI776882B (zh)
UA (1) UA124364C2 (zh)
WO (1) WO2018194356A1 (zh)
ZA (1) ZA201907687B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
WO2020125391A1 (zh) * 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的氨基嘧啶类化合物
WO2020174370A2 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2020230091A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
KR20220010731A (ko) * 2019-05-14 2022-01-26 얀센 바이오테크 인코포레이티드 이중특이성 항-EGFR/c-Met 항체와 제3 세대 EGFR 티로신 키나제 억제제에 의한 병용 요법
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CN117425651A (zh) 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698623E (pt) 2003-12-25 2015-06-29 Eisai R&D Man Co Ltd Cristal de sal de 4-(3-cloro-4-(ciclopropilaminocarbonil)amino fenoxi)-7-metoxi-6-quinolinacarboxamida ou de seu solvato e rocesso para produção destes
WO2005077933A1 (en) 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
JP2011526299A (ja) * 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
US9006448B2 (en) * 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
ES2900230T3 (es) 2011-07-27 2022-03-16 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
PL3207035T3 (pl) 2014-10-13 2020-06-01 Yuhan Corporation Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma

Also Published As

Publication number Publication date
AR111469A1 (es) 2019-07-17
JP7126514B2 (ja) 2022-08-26
JP7390444B2 (ja) 2023-12-01
AU2018256227A1 (en) 2019-10-31
AU2022203486B2 (en) 2024-06-06
US20230021395A1 (en) 2023-01-26
EP3612529A1 (en) 2020-02-26
PH12019502370A1 (en) 2020-07-13
IL270018A (zh) 2019-12-31
CA3059543A1 (en) 2018-10-25
US20210139461A1 (en) 2021-05-13
AU2018256227B2 (en) 2022-03-03
KR20180118535A (ko) 2018-10-31
AU2022203486A1 (en) 2022-06-09
CO2019011578A2 (es) 2020-02-28
TW201841910A (zh) 2018-12-01
EA201992501A1 (ru) 2020-02-18
UA124364C2 (uk) 2021-09-01
NZ758443A (en) 2023-03-31
KR102629654B1 (ko) 2024-01-29
WO2018194356A1 (en) 2018-10-25
US20240279203A1 (en) 2024-08-22
CN110869367B (zh) 2023-09-15
MA49696A (fr) 2020-06-03
SG11201909615YA (en) 2019-11-28
EP3612529A4 (en) 2020-11-18
IL294666B2 (en) 2024-05-01
MY201919A (en) 2024-03-23
IL270018B (en) 2022-08-01
CN110869367A (zh) 2020-03-06
MX2022006357A (es) 2022-06-23
TWI776882B (zh) 2022-09-11
IL294666A (en) 2022-09-01
IL294666B1 (en) 2024-01-01
KR20230175161A (ko) 2023-12-29
JP2022166179A (ja) 2022-11-01
US11981659B2 (en) 2024-05-14
US11453656B2 (en) 2022-09-27
SA519410342B1 (ar) 2023-02-09
JP2020517611A (ja) 2020-06-18
BR112019021868A2 (pt) 2020-05-26

Similar Documents

Publication Publication Date Title
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
IL273821B (en) A stereoselective process for the preparation of modified polycyclic pyridine derivatives
HUE052796T2 (hu) Eljárás 4-ammónium-2,2,6,6-tetraalkilpiperidinil-sók elõállítására
EP3706725A4 (en) PROCESS FOR THE PREPARATION OF TAPINAROF
EP3617185A4 (en) METHOD FOR PREPARING AN AMIDE COMPOUND
IL265536A (en) A method for the production of a crystalline form of the a modification of calcobuterol
EP3611253A4 (en) METHOD FOR PRODUCING THEANINE
EP3620451A4 (en) PROCESS FOR THE PRODUCTION OF 2,3-DICHLORO-5-TRIFLUOROMETHYLPYRIDINE WITH HIGH SELECTIVITY
EP3733648A4 (en) PROCESS FOR THE MANUFACTURING OF 5R-BENZYLOXYAMINOPIPERIDINE-2S-CARBONIC ACID OR DERIVATIVE THEREOF
IL275434B (en) A method for preparing a thiocarboxamidine salt compound
EP3363796A4 (en) PROCESS FOR PREPARING A HETEROCYCLIC COMPOUND
EP3643701A4 (en) PROCESS FOR PRODUCING A COMPOUND
EP3353149A4 (en) PROCESS FOR THE PREPARATION OF INDOLIN COMPOUNDS AND A NOVEL INDOLIN SALT
RS62449B1 (sr) So derivata cefalosporina, njen kristalni čvrst oblik i postupak njene proizvodnje
EP3613730A4 (en) PROCESS FOR PREPARING A PYRIDAZINE COMPOUND
EP3652158A4 (en) METHOD FOR PRODUCING A PYRIMIDONE COMPOUND
IL273639A (en) A process for the preparation of pyrrolidine alpha-carboxamide derivatives
EP3681880A4 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE TIPIRACIL HYDROCHLORIDE
EP3717452A4 (en) PROCESS FOR THE PREPARATION OF ACYLATED AMPHETAMINE DERIVATIVES
EP3502059A4 (en) PROCESS FOR THE PREPARATION OF POTASSIUM TITANATE
GB201600977D0 (en) Novel crystalline form of picoxystrobin, method of preparing use of the same
IL271512B (en) A method for the preparation of modified 4-aminoindan derivatives
EP3704109C0 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM III OF TIPIRACIL HYDROCHLORIDE
EP3590936A4 (en) METHOD OF MAKING A HETEROCYCLIC COMPOUND
PL3632917T3 (pl) Sposób wytwarzania pochodnych heterocyklicznych